Dr. Reddy's Laboratories stock reports USD 32,350 IRS penalty as earnings reset
Published on 10/05/2026 at 22:20 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Dr. Reddy's Laboratories (ISIN US2561352038) was trading at USD 12.31 on the NYSE on October 5, 2026 at 2:35:59 p.m. ET, up 0.45 percent on the session. The company also disclosed a USD 32,350.20 IRS penalty for a wholly owned subsidiary in a filing dated October 3, 2026, while assessing the impact on its financials and operations as immaterial, according to StockTitan.
IRS filing sets a small financial marker
The filing identifies a tax-payment classification error at Dr. Reddy's Laboratories, Inc., the company's step-down subsidiary. The amount is small beside the group's market capitalization of USD 10.3 billion as of October 5, 2026, so the filing is more relevant as a disclosure point than as an earnings driver.
The filing says the IRS transcript was received on October 2, 2026, and dated September 25, 2026. The company linked the penalty to a fiscal-year reference being misclassified when the tax payment was made, according to StockTitan.
Q1 revenue misses forecast
The operating picture is more consequential. For Q1 fiscal 2027, revenue was USD 853 million against a USD 858.61 million forecast, a shortfall of 0.65 percent, while EPS was USD 0.06 against USD 0.09 expected, according to Investing.com.
That EPS result was 33.3 percent below the forecast figure. The same earnings summary says a semaglutide API issue led to an INR 240 crore provision and a production halt, while normalized operations remain tied to a 20 percent EBITDA margin target, according to Investing.com.
Analyst targets and October earnings date
Citi upgraded Dr. Reddy's Laboratories to Buy from Sell on September 29, 2026, and raised its target to INR 1,450 from INR 1,040. The brokerage also estimated that Abatacept and semaglutide could add USD 350 million to USD 400 million to revenue across fiscal years 2027 to 2029, as CNBC TV18 reported.
The broader consensus is Neutral from five analysts, with an average 12-month target of USD 13.29, a high estimate of USD 15.30597216 and a low estimate of USD 11.29267761. That average target stands 7.96 percent above the NYSE price, according to Investing.com.
NYSE quote stays below yearly high
RDY's October 5 trading range was USD 12.17 to USD 12.33, while its 52-week range was USD 11.36 to USD 15.67. The stock's USD 12.31 price therefore stood 21.4 percent below the 52-week high, leaving the next earnings date on October 23, 2026 as the clearest scheduled checkpoint.
Dr. Reddy's Laboratories stock details
- Company: Dr. Reddy's Laboratories Limited
- ISIN: US2561352038
- Ticker: RDY
- Trading venue: NYSE
- Price (as of October 5, 2026, 2:35:59 p.m. ET): USD 12.31
- Market capitalization: USD 10.3 billion (as of October 5, 2026)
- 52-week range: USD 11.36-15.67 (as of October 5, 2026)
- Sector / Industry: Healthcare / Pharmaceuticals
Upcoming dates for Dr. Reddy's Laboratories stock
- October 23, 2026: Next earnings report
